

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

Cost comparison - Etrasimod for treating moderately to severely active ulcerative colitis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| During scoping, stakeholders highlighted certain socioeconomic challenges relating to the cost of prescription medications and that this may be a barrier to well-being and adherence. However, prescription charges are outside of the committee's remit. |
| Stakeholders also highlighted that the mode of administration could benefit those with disabilities in terms of reducing the need to travel to hospital and that being able to take their treatment at home may also benefit cultures where it may be harder to speak openly about the condition or for those living in remote communities. There are several oral treatments in the pathway already recommended for ulcerative colitis, and it was considered that recommending etrasimod provides an additional treatment option which may aid administration for these people. |

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No. |

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

N/A

Approved by Associate Director (name):Janet Robertson.....

Date: 11/01/24